№ files_lp_3_process_7_056346
File format: docx
Character count: 182822
File size: 1222 KB
A report analyzing the cost-effectiveness of various smoking cessation medicines and the potential impact on the Pharmaceutical Benefits Scheme for specified combinations of medicines.
Year:
2021
Region / City:
Australia
Topic:
Smoking cessation, medicines cost-effectiveness, Pharmaceutical Benefits Scheme
Document type:
Report
Organization:
Pharmaceutical Benefits Advisory Committee
Author:
Centre for Health Economics, Monash University
Target audience:
Health professionals, policy makers, Pharmaceutical Benefits Advisory Committee members
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Purpose:
Post-market review, cost-effectiveness evaluation
Clinical issue:
Smoking cessation treatment
Proposed changes to PBS restrictions:
Yes
Market size:
Pharmacological assisted quit attempts
Treatment costs and co-payments:
Yes
Market growth:
Change in quit attempts
Health outcomes:
Quit rates, relapse rates, smoking-related diseases
References:
Yes
Note:
Contextual description
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
XXXX
Region / city:
XXXX
Topic:
Medical Device Safety and Performance Evaluation
Document Type:
Evaluation Report
Organization / Institution:
XXXX
Author:
XXXX
Target Audience:
Regulatory Bodies, Medical Device Manufacturers
Period of Effectiveness:
XXXX
Approval Date:
XXXX
Date of Changes:
XXXX
Year:
YYYY
Region / City:
[City/Region]
Topic:
Medical Device Safety and Performance Monitoring
Document Type:
PMCF Plan
Organization:
[Manufacturer Name]
Author:
[Author Name]
Target Audience:
Regulatory Authorities, Medical Device Manufacturers
Validity Period:
YYYY/MM/DD to YYYY/MM/DD
Approval Date:
DD/MM/YYYY
Revision Date:
XXXX
Date of Changes:
YYYY/MM/DD
Year:
2015
Region / city:
International
Topic:
Medical Device Regulation
Document Type:
Official Report
Organization / Institution:
International Medical Device Regulators Forum (IMDRF)
Author:
National Competent Authority Report Working Group
Target Audience:
Medical Device Regulators, Public Health Authorities
Period of validity:
Ongoing
Approval Date:
26 March 2015
Date of amendments:
None
Year:
2016-2017
Region / city:
Australia
Topic:
Life Saving Drugs Program, Rare Diseases, Health Policy
Document type:
Government Report
Organization / institution:
Australian Government
Author:
Australian Government
Target audience:
Health policymakers, healthcare professionals, stakeholders in rare disease treatment
Period of validity:
Ongoing
Date of approval:
2014-04-09
Date of amendments:
None
Year:
2023
Region / City:
Australia
Subject:
Smoking cessation, pharmaceutical benefits
Document Type:
Report
Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Unknown
Target Audience:
Healthcare providers, policymakers
Period of Effect:
Ongoing
Approval Date:
Unknown
Date of Changes:
Unknown
Year:
2023
Region / City:
Australia
Topic:
Opioid Dependence Treatment, Pharmaceutical Benefits Scheme
Document Type:
Government Report
Organization:
Australian Government Department of Health and Aged Care
Author:
Australian Government Department of Health and Aged Care
Target Audience:
Stakeholders, policymakers, healthcare providers, public
Effective Period:
2023-07-01 and onwards
Approval Date:
2023-03-01
Modification Date:
N/A
Interim Review Outcomes Date:
2023-03-01
Note:
Contextual Description
Year:
2019
Region / Country:
Australia
Subject:
Pulmonary arterial hypertension medicines and subsidy policy
Document Type:
Policy review agenda item and briefing
Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Program:
Pharmaceutical Benefits Scheme (PBS)
Topic:
Post-Market Review (PMR) of PAH medicines
Medicines Mentioned:
bosentan, ambrisentan, macitentan, sildenafil, tadalafil, iloprost, riociguat, epoprostenol
Medical Classification Referenced:
WHO Functional Class II–IV pulmonary arterial hypertension
Guidelines Referenced:
2015 European Society of Cardiology / European Respiratory Society Guidelines for the diagnosis and treatment of pulmonary hypertension
Stakeholders:
PAH Reference Group, medicine sponsors including Actelion, GlaxoSmithKline, and Pfizer
Regulatory Focus:
Revision of PBS prescribing restrictions and subsidy conditions
Key Policy Changes Considered:
Extension of subsidised monotherapy to WHO Functional Class II patients, updated PAH definition, inclusion of additional WHO Group 1 PAH subtypes, removal of calcium channel blocker trial requirement, strengthened diagnostic role of right heart catheterisation
Consultation Process:
Pre-PBAC consultation with sponsors and reference group
Associated Meetings:
PBAC meetings in November 2018, March 2019, and planned July 2019 review discussion
Related Policy Activity:
Planned stakeholder meeting on PAH combination therapy scheduled for May 2019
Year:
2021
Region / city:
England, Wales
Theme:
Cost-effectiveness, medical imaging, coronary artery disease
Document type:
Research study
Organization / institution:
National Health Service (NHS)
Author:
Not specified
Target audience:
Healthcare professionals, researchers, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2023
Region / city:
Australia
Subject:
Pharmaceutical treatment for primary biliary cholangitis
Document type:
Authority submission for PBS listing
Organization:
Emerge Health Pty Ltd
Author:
Emerge Health Pty Ltd
Target audience:
Healthcare professionals, gastroenterologists, hepatologists, prescribers
Period of validity:
Ongoing
Approval date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / City:
Not specified
Topic:
Safety, efficacy, cost-effectiveness of nitrofurantoin in pregnancy
Document Type:
Research article
Organization / Institution:
Journal of Advances in Medicine and Medical Research
Author:
DR (Created by), PM (Checked by), MBM (Approved by)
Target Audience:
Scientific community, healthcare professionals
Period of validity:
Not specified
Approval Date:
07-07-2024
Date of Changes:
Not specified
Ethical Issues:
Not specified
Keywords:
Nitrofurantoin, pregnancy, urinary tract infections, cost-effectiveness, safety, efficacy
Language:
English
Sample Size:
180 participants
Study Design:
Single-center study
Limitations:
Single-center design, no control group, lack of G6PD screening, small sample size, no long-term follow-up of neonatal outcomes
Contextual Description:
Research article exploring the safety, efficacy, and cost-effectiveness of nitrofurantoin for urinary tract infections in pregnancy, highlighting various study limitations and areas for future research.
Year:
2025
Region / City:
United States, California
Topic:
Energy efficiency, Heat pump systems, Cost-effectiveness analysis
Document type:
Research study
Organization:
Pacific Gas and Electric Company, Frontier Energy Inc.
Author:
Kelly Cunningham, Misti Bruceri & Associates, LLC
Target Audience:
Energy program administrators, policymakers, building professionals
Period of validity:
2025
Approval Date:
2025/08/08
Modification Date:
2025/08/08
Year:
2021
Region / City:
Southeast Asia
Topic:
Cost-effectiveness analysis of non-communicable disease prevention strategies
Document Type:
Research Supplementary Material
Organization:
Various health institutions in Southeast Asia
Author:
Thi-Phuong-Lan Nguyen, M. Rifqi Rokhman, Imre Stiensma, Rachmadianti Sukma Hanifa, Due Ong The, Maarten J. Postma, Jurjen van der Schans
Target Audience:
Health policy makers, researchers in public health
Period of Effect:
Not specified
Approval Date:
Not provided
Date of Changes:
Not provided
Context:
The document provides a cost-effectiveness analysis of different prevention strategies for cardiovascular diseases in Southeast Asia.
Year:
2023
Region / City:
United States
Topic:
Health Economics, Neonatal Care
Document Type:
Supplemental Material / Research Table and Figure
Institution:
Academic Medical Center / Research Group
Authors:
Not specified
Target Audience:
Health economists, neonatologists, researchers
Analysis Period:
Short-term (hospital stay) and long-term (childhood)
Data Currency:
US Dollars
Health Conditions Covered:
Intestinal failure-associated liver disease (IFALD), necrotizing enterocolitis, sepsis
Outcomes Measured:
Hospital costs, long-term disability, chronic liver disease, QALY
Methodology:
Cost-effectiveness analysis, transition probabilities, incremental cost-effectiveness ratio (ICER)
Model Population:
Surgical neonates at risk of IFALD and related complications
Year:
2023
Region / City:
Akosombo, Eastern Region, Ghana
Type of Document:
Original Research Article
Institution:
Aquaculture Research and Development Centre (ARDEC), Water Research Institute (WRI), Council for Scientific and Industrial Research (CSIR)
Species Studied:
Nile tilapia (Oreochromis niloticus), African catfish (Clarias gariepinus)
Experimental Duration:
77 days
Feed Types:
Commercial tilapia feed, commercial catfish feed, 1:1 mixture
Key Variables:
Growth performance, cost-effectiveness, profit index
Methodology:
Hapa-in-pond system, manual feeding 3 times daily
Target Audience:
Fish farmers, aquaculture researchers
Experimental Design:
Three treatments (A: tilapia feed, B: catfish feed, C: feed mixture)
Start Date:
July 2023
End Date:
September 2023
Context:
Peer-reviewed aquaculture study evaluating the growth and economic efficiency of mixed-species fingerling rearing using different commercial feed strategies in a pond-based experimental system.
Year:
2021
Region:
California, United States
Document Type:
Regulatory resolution
Institution:
California Public Utilities Commission – Energy Division
Resolution Number:
E-5150
Adoption Date:
June 24, 2021
Subject:
Updates to the Avoided Cost Calculator for distributed energy resource cost-effectiveness analysis
Policy Context:
Distributed Energy Resource (DER) policy and regulatory cost-effectiveness framework
Related Decisions:
D.16-06-007; D.19-05-019; D.20-04-010
Referenced Proceedings:
Integrated Distributed Energy Resources Rulemaking (R.14-10-003); Integrated Resource Planning (R.16-02-007); Distributed Resource Planning (R.14-08-013)
Key Analytical Tool:
Avoided Cost Calculator (ACC)
Update Type:
Minor data updates and modeling adjustments
Primary Data Sources Mentioned:
California Energy Commission Integrated Energy Policy Report (IEPR); IRP modeling outputs; Lazard Levelized Cost of Storage Study 5.0
Stakeholder Process:
Energy Division workshop and stakeholder comments in 2020
Estimated Cost Impact:
No incremental cost
Policy Area:
Energy regulation and distributed energy resources
Year:
2015
Region / City:
London, UK
Theme:
Health Economics, Physical Activity Interventions
Document Type:
Research Article
Author:
N Anokye, J Fox-Rushby, S Sanghera, D G Cook, S M Kerry, E Limb, C R Victor, S Iliffe, S M Shah, M Ussher, P H Whincup, U Ekelund, C Furness, J Ibison, S DeWilde, L David, E Howard, R Dale, J Smith, T J Harris
Target Audience:
Health researchers, policymakers, healthcare professionals
Period of Effectiveness:
2012–2014
Approval Date:
2015
Modification Date:
Not specified
Funding:
National Institute for Health Research Health Technology Assessment Programme (project number HTA 10/32/02 ISRCTN42122561)
Ethics Approval:
London Research Ethics Committee (Hampstead)
Trial Registration:
ISRCTN98538934
Year:
2010–2011
Region:
United Kingdom, England
Subject:
Telehealth, Chronic Obstructive Pulmonary Disease (COPD), Health Economics
Document type:
Research Study / Pilot Programme Report
Organization:
National Health Service Direct (NHSD)
Authors:
Not specified
Target population:
Patients with chronic obstructive pulmonary disease (COPD)
Study sites:
Two Primary Care Trusts (PCT1, PCT2)
Participants:
321 enrolled, 227 included in final analysis
Intervention:
Remote patient monitoring / telehealth
Outcome measures:
Cost-effectiveness, resource utilization, hospital admissions, length of stay
Data collection period:
12 months before, immediately before, and during monitoring
Keywords:
telehealth, telemedicine, cost-effectiveness, remote patient monitoring
Year:
2016
Region / city:
Boston, MA
Topic:
Smoking cessation, public health
Document type:
Research article
Organization:
Boston University School of Public Health, Harvard T.H. Chan School of Public Health, Boston Housing Authority
Author:
Daniel R. Brooks, Joanna Burtner, Belinda Borrelli, Timothy C. Heeren, Tegan Evans, Jessica Davine, Jonathan Greenbaum, Matthew Scarpaci, John Kane, Vaughan W. Rees, Alan C. Geller
Target audience:
Public health professionals, researchers, policymakers
Period of validity:
2012-2016
Approval date:
2016
Date of changes:
None
Year:
2025
Region / city:
United States
Subject:
Nuclear reactor inspection
Document type:
Manual
Organization / institution:
Nuclear Regulatory Commission (NRC)
Author:
NRC
Target audience:
NRC staff, reactor facility operators, regulatory bodies
Period of validity:
From April 24, 2025
Approval date:
April 24, 2025
Date of amendments:
Not provided